Key facts
- Notable investors include Suzhou Oriza Holdings Corporation, Innoval Capital, Nanjing Innovation Capital Group, Zhidao Capital, Wanchuang Huahui Investment Management — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Mingche
- ·The full record, as it builds
Funding rounds
No funding rounds for Mingche are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mingche
Developer and producer of optometry medical devices designed for minimally invasive eye surgery. The company's devices include a multi-product line layout of ocular micro-device such as minimally invasive glaucoma drainage tube (MIGS) as the core, sensor platform, microneedle drug delivery platform and magnetically controlled surgical robot platform, enabling health care professionals to perform minimally invasive, efficient and simple eye surgery.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Mingche doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mingche shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mingche in its N-PORT filings yet. We sweep new filings monthly.